成年跨性别者中银屑病的患病率及与激素治疗的感知关联。
Prevalence of Psoriasis and Perceived Association with Hormone Therapy in Transgender Adults.
作者信息
Braun Hayley, Thompson Elaine C, Zhang Qi, Tangpricha Vin, Goodman Michael, Yeung Howa
机构信息
Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
出版信息
Transgend Health. 2023 Jul 28;8(4):396-399. doi: 10.1089/trgh.2021.0104. eCollection 2023 Aug.
PURPOSE
The role of hormone therapy (HT) in the etiology and progression of psoriasis in the transgender population is unclear.
METHODS
The prevalence of psoriasis in transmasculine (TM) and transfeminine (TF) adults and perceived links between psoriasis and gender-affirming HT is examined using a cross-sectional survey of 696 transgender individuals.
RESULTS
Ever diagnosis of psoriasis was reported by 17 TM persons (4.9%; 95% confidence interval [CI]: 2.6-7.2) and 13 TF persons (3.7%; 95% CI: 1.7-5.7). Prevalence of current psoriasis in TM persons was 2.6% (95% CI: 0.9-4.3) and 1.1% (95% CI: 0.03-2.3) among TF persons. Notably, among participants who had ever had psoriasis, 17% perceived a link between their psoriasis and gender-affirming HT.
CONCLUSIONS
Prevalence of psoriasis among transgender persons resembled estimates in the general population. Potential associations between psoriasis and its severity with gender-affirming HT warrant further longitudinal research.
目的
激素疗法（HT）在跨性别群体银屑病的病因和进展中的作用尚不清楚。
方法
通过对696名跨性别个体进行横断面调查，研究了男性化跨性别者（TM）和女性化跨性别者（TF）中银屑病的患病率以及银屑病与性别确认激素疗法之间的潜在联系。
结果
17名TM个体（4.9%；95%置信区间[CI]：2.6 - 7.2）和13名TF个体（3.7%；95%CI：1.7 - 5.7）报告曾被诊断为银屑病。TM个体中当前银屑病的患病率为2.6%（95%CI：0.9 - 4.3），TF个体中为1.1%（95%CI：0.03 - 2.3）。值得注意的是，在曾患银屑病的参与者中，17%认为他们的银屑病与性别确认激素疗法之间存在联系。
结论
跨性别者中银屑病的患病率与一般人群的估计值相似。银屑病及其严重程度与性别确认激素疗法之间的潜在关联值得进一步进行纵向研究。
Zotero 插件